Related Experiment Video
Updated: Jul 3, 2026
08:47
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies
Yujinpeng Hao1, Jun Shao1, Naqi Lian2
1The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Pharmacology Research & Perspectives
|July 1, 2026
Summary
Eukaryotic translation initiation factor 3 subunit F (eIF3f) has dual roles in cancer, acting as an oncogene in some cancers and a tumor suppressor in others. Understanding its context-dependent functions is key for developing targeted therapies.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Eukaryotic translation initiation factor 3 subunit F (eIF3f) is integral to the eIF3 complex, influencing cell proliferation, apoptosis, and transcription.
- Aberrant eIF3f expression is observed in various cancers, with a context-dependent role in tumor progression.
Purpose of the Study:
- To systematically review the structural characteristics, biological functions, and expression patterns of eIF3f across malignancies.
- To propose a mechanistic framework for eIF3f's functional plasticity and evaluate its potential as a biomarker.
- To identify challenges and future directions for eIF3f-targeted cancer therapies.
Main Methods:
- Systematic literature review and analysis of eIF3f's role in different cancer types.
- Integration of data on eIF3f expression, post-translational modifications, and tumor microenvironment interactions.
- Critical evaluation of diagnostic/prognostic biomarker potential and therapeutic targeting strategies.
Main Results:
- eIF3f exhibits oncogenic roles in hepatocellular carcinoma, colorectal cancer, and prostate cancer, but tumor-suppressive functions in pancreatic cancer and melanoma.
- Functional plasticity is attributed to differential upstream signaling, post-translational modifications, and tumor microenvironment remodeling.
- Evidence for eIF3f as a biomarker is variable, with challenges in current therapeutic strategies.
Conclusions:
- eIF3f's dual role necessitates context-specific understanding for effective therapeutic strategies.
- Further research into eIF3f's structural biology and context-dependent mechanisms is crucial.
- Developing precision, stratified therapeutic approaches for eIF3f is a priority for clinical translation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...